# Alpha Teknova, Inc.: financial statements, quarterly

TKNO · Nasdaq · CIK 1850902 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tkno.md) · [Financials](/companies/tkno/financials.md) · [Filings](/companies/tkno/filings.md) · [Insiders](/companies/tkno/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tkno/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.2](/filings/0000950170-24-124159.md) | [7.9 d](/filings/0000950170-25-035705.md) | [9.3](/filings/0000950170-25-068050.md) | [9.6](/filings/0000950170-25-105825.md) | [9.6](/filings/0001193125-25-272321.md) | [9.3 d](/filings/0001850902-26-000002.md) | [9.8](/filings/0001850902-26-000008.md) | [10.3](/filings/0001193125-26-338178.md) | [10.5](/filings/0001193125-25-272321.md) | [10.0 d](/filings/0001850902-26-000002.md) | [11.1](/filings/0001850902-26-000008.md) | [12.2](/filings/0001193125-26-338178.md) |
| Cost of revenue | $m | [6.7](/filings/0000950170-24-124159.md) | [6.5 d](/filings/0000950170-25-035705.md) | [7.1](/filings/0000950170-25-068050.md) | [6.8](/filings/0000950170-25-105825.md) | [9.5](/filings/0001193125-25-272321.md) | [7.1 d](/filings/0001850902-26-000002.md) | [6.8](/filings/0001850902-26-000008.md) | [6.3](/filings/0001193125-26-338178.md) | [7.2](/filings/0001193125-25-272321.md) | [6.7 d](/filings/0001850902-26-000002.md) | [7.3](/filings/0001850902-26-000008.md) | [7.3](/filings/0001193125-26-338178.md) |
| Gross profit | $m | [1.5](/filings/0000950170-24-124159.md) | [1.3 d](/filings/0000950170-25-035705.md) | [2.2](/filings/0000950170-25-068050.md) | [2.8](/filings/0000950170-25-105825.md) | [0.1](/filings/0001193125-25-272321.md) | [2.1 d](/filings/0001850902-26-000002.md) | [3.0](/filings/0001850902-26-000008.md) | [4.0](/filings/0001193125-26-338178.md) | [3.2](/filings/0001193125-25-272321.md) | [3.2 d](/filings/0001850902-26-000002.md) | [3.8](/filings/0001850902-26-000008.md) | [4.9](/filings/0001193125-26-338178.md) |
| Research and development | $m | [1.4](/filings/0000950170-24-124159.md) | [1.3 d](/filings/0000950170-25-035705.md) | [0.9](/filings/0000950170-25-068050.md) | [0.7](/filings/0000950170-25-105825.md) | [0.6](/filings/0001193125-25-272321.md) | [0.6 d](/filings/0001850902-26-000002.md) | [0.6](/filings/0001850902-26-000008.md) | [0.6](/filings/0001193125-26-338178.md) | [0.5](/filings/0001193125-25-272321.md) | [0.5 d](/filings/0001850902-26-000002.md) | [0.6](/filings/0001850902-26-000008.md) | [0.6](/filings/0001193125-26-338178.md) |
| Operating income | $m | [(8.8)](/filings/0000950170-24-124159.md) | [(10.9) d](/filings/0000950170-25-035705.md) | [(8.0)](/filings/0000950170-25-068050.md) | [(5.1)](/filings/0000950170-25-105825.md) | [(7.4)](/filings/0001193125-25-272321.md) | [(5.6) d](/filings/0001850902-26-000002.md) | [(5.0)](/filings/0001850902-26-000008.md) | [(3.4)](/filings/0001193125-26-338178.md) | [(4.0)](/filings/0001193125-25-272321.md) | [(4.6) d](/filings/0001850902-26-000002.md) | [(4.3)](/filings/0001850902-26-000008.md) | [(2.9)](/filings/0001193125-26-338178.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-124159.md) | [(0.3) d](/filings/0000950170-25-035705.md) | [(0.0)](/filings/0000950170-25-068050.md) | [(0.0)](/filings/0000950170-25-105825.md) | [(0.0)](/filings/0001193125-25-272321.md) | [(0.0) d](/filings/0001850902-26-000002.md) | [0.0](/filings/0001850902-26-000008.md) | [0.0](/filings/0001193125-26-338178.md) | [0.1](/filings/0001193125-25-272321.md) | [(0.1) d](/filings/0001850902-26-000002.md) | [0.0](/filings/0001850902-26-000008.md) | [0.0](/filings/0001193125-26-338178.md) |
| Net income | $m | [(10.2)](/filings/0000950170-24-124159.md) | [(10.7) d](/filings/0000950170-25-035705.md) | [(8.1)](/filings/0000950170-25-068050.md) | [(5.4)](/filings/0000950170-25-105825.md) | [(7.6)](/filings/0001193125-25-272321.md) | [(5.7) d](/filings/0001850902-26-000002.md) | [(4.6)](/filings/0001850902-26-000008.md) | [(3.6)](/filings/0001193125-26-338178.md) | [(4.3)](/filings/0001193125-25-272321.md) | [(4.8) d](/filings/0001850902-26-000002.md) | [(4.6)](/filings/0001850902-26-000008.md) | [(3.2)](/filings/0001193125-26-338178.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0000950170-24-124159.md) | not reported | [(0.20)](/filings/0000950170-25-068050.md) | [(0.13)](/filings/0000950170-25-105825.md) | [(0.15)](/filings/0001193125-25-272321.md) | not reported | [(0.09)](/filings/0001850902-26-000008.md) | [(0.07)](/filings/0001193125-26-338178.md) | [(0.08)](/filings/0001193125-25-272321.md) | not reported | [(0.08)](/filings/0001850902-26-000008.md) | [(0.06)](/filings/0001193125-26-338178.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0000950170-24-124159.md) | not reported | [(0.20)](/filings/0000950170-25-068050.md) | [(0.13)](/filings/0000950170-25-105825.md) | [(0.15)](/filings/0001193125-25-272321.md) | not reported | [(0.09)](/filings/0001850902-26-000008.md) | [(0.07)](/filings/0001193125-26-338178.md) | [(0.08)](/filings/0001193125-25-272321.md) | not reported | [(0.08)](/filings/0001850902-26-000008.md) | [(0.06)](/filings/0001193125-26-338178.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [32.1](/filings/0000950170-23-063053.md) | [28.5](/filings/0000950170-25-035705.md) | [21.6](/filings/0000950170-24-058827.md) | [18.6](/filings/0000950170-24-096441.md) | [6.1](/filings/0000950170-24-124159.md) | [3.7](/filings/0001850902-26-000002.md) | [3.4](/filings/0000950170-25-068050.md) | [3.3](/filings/0000950170-25-105825.md) | [3.2](/filings/0001193125-25-272321.md) | [5.9](/filings/0001193125-26-338178.md) | [4.3](/filings/0001850902-26-000008.md) | [6.0](/filings/0001193125-26-338178.md) |
| Current assets | $m | [51.1](/filings/0000950170-23-063053.md) | [45.7](/filings/0000950170-25-035705.md) | [38.8](/filings/0000950170-24-058827.md) | [35.3](/filings/0000950170-24-096441.md) | [45.9](/filings/0000950170-24-124159.md) | [42.8](/filings/0001850902-26-000002.md) | [39.7](/filings/0000950170-25-068050.md) | [38.1](/filings/0000950170-25-105825.md) | [36.6](/filings/0001193125-25-272321.md) | [34.5](/filings/0001193125-26-338178.md) | [31.7](/filings/0001850902-26-000008.md) | [30.8](/filings/0001193125-26-338178.md) |
| Total assets | $m | [138](/filings/0000950170-23-063053.md) | [129](/filings/0000950170-25-035705.md) | [121](/filings/0000950170-24-058827.md) | [115](/filings/0000950170-24-096441.md) | [124](/filings/0000950170-24-124159.md) | [119](/filings/0001850902-26-000002.md) | [114](/filings/0000950170-25-068050.md) | [110](/filings/0000950170-25-105825.md) | [108](/filings/0001193125-25-272321.md) | [104](/filings/0001193125-26-338178.md) | [98.7](/filings/0001850902-26-000008.md) | [95.9](/filings/0001193125-26-338178.md) |
| Current liabilities | $m | [8.3](/filings/0000950170-23-063053.md) | [8.9](/filings/0000950170-25-035705.md) | [7.0](/filings/0000950170-24-058827.md) | [7.4](/filings/0000950170-24-096441.md) | [9.7](/filings/0000950170-24-124159.md) | [11.2](/filings/0001850902-26-000002.md) | [7.0](/filings/0000950170-25-068050.md) | [6.5](/filings/0000950170-25-105825.md) | [6.9](/filings/0001193125-25-272321.md) | [7.5](/filings/0001193125-26-338178.md) | [6.9](/filings/0001850902-26-000008.md) | [6.9](/filings/0001193125-26-338178.md) |
| Total liabilities | $m | [38.7](/filings/0000950170-23-063053.md) | [38.6](/filings/0000950170-25-035705.md) | [37.4](/filings/0000950170-24-058827.md) | [36.4](/filings/0000950170-24-096441.md) | [36.8](/filings/0000950170-24-124159.md) | [36.4](/filings/0001850902-26-000002.md) | [35.4](/filings/0000950170-25-068050.md) | [34.4](/filings/0000950170-25-105825.md) | [35.0](/filings/0001193125-25-272321.md) | [34.8](/filings/0001193125-26-338178.md) | [33.7](/filings/0001850902-26-000008.md) | [33.3](/filings/0001193125-26-338178.md) |
| Long-term debt | $m | [13.2](/filings/0000950170-23-063053.md) | [13.3](/filings/0000950170-24-124159.md) | [13.2](/filings/0000950170-24-058827.md) | [12.3](/filings/0000950170-24-096441.md) | [10.9](/filings/0000950170-24-124159.md) | [9.4](/filings/0001850902-26-000002.md) | [13.0](/filings/0000950170-25-068050.md) | [13.0](/filings/0000950170-25-105825.md) | [13.1](/filings/0001193125-25-272321.md) | [13.1](/filings/0001193125-26-338178.md) | [13.2](/filings/0001850902-26-000008.md) | [13.2](/filings/0001193125-26-338178.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-035705.md) | not reported | [1.0](/filings/0000950170-24-096441.md) | [2.5](/filings/0000950170-24-124159.md) | [4.0](/filings/0001850902-26-000002.md) | [0.0](/filings/0000950170-25-068050.md) | [0.0](/filings/0000950170-25-105825.md) | [0.0](/filings/0001193125-25-272321.md) | [0.0](/filings/0001850902-26-000002.md) | not reported | not reported |
| Shareholders' equity | $m | [99.7](/filings/0000950170-24-124159.md) | [90.0](/filings/0001850902-26-000002.md) | [83.4](/filings/0000950170-25-105825.md) | [78.9](/filings/0001193125-25-272321.md) | [87.3](/filings/0001193125-25-272321.md) | [82.4](/filings/0001193125-26-338178.md) | [78.6](/filings/0001193125-26-338178.md) | [76.1](/filings/0001193125-26-338178.md) | [72.7](/filings/0001193125-25-272321.md) | [68.8](/filings/0001193125-26-338178.md) | [64.9](/filings/0001193125-26-338178.md) | [62.6](/filings/0001193125-26-338178.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,382) d](/filings/0000950170-24-124159.md) | [(2,892) d](/filings/0000950170-25-035705.md) | [(6,558)](/filings/0000950170-25-068050.md) | [(2,838) d](/filings/0000950170-25-105825.md) | [(2,059) d](/filings/0001193125-25-272321.md) | [(936) d](/filings/0001850902-26-000002.md) | [(4,103)](/filings/0001850902-26-000008.md) | [(2,101) d](/filings/0001193125-26-338178.md) | [(1,980) d](/filings/0001193125-25-272321.md) | [(462) d](/filings/0001850902-26-000002.md) | [(3,359)](/filings/0001850902-26-000008.md) | [(471) d](/filings/0001193125-26-338178.md) |
| Capital expenditure | $k | [972 d](/filings/0000950170-24-124159.md) | [312 d](/filings/0000950170-25-035705.md) | [112](/filings/0000950170-25-068050.md) | [115 d](/filings/0000950170-25-105825.md) | [331 d](/filings/0001193125-25-272321.md) | [567 d](/filings/0001850902-26-000002.md) | [206](/filings/0001850902-26-000008.md) | [207 d](/filings/0001193125-26-338178.md) | [387 d](/filings/0001193125-25-272321.md) | [348 d](/filings/0001850902-26-000002.md) | [221](/filings/0001850902-26-000008.md) | [125 d](/filings/0001193125-26-338178.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.1](/filings/0000950170-23-063053.md) | [28.2](/filings/0000950170-24-058827.md) | [28.3](/filings/0000950170-24-096441.md) | [30.0](/filings/0000950170-24-124159.md) | [40.8](/filings/0000950170-25-068050.md) | [40.9](/filings/0000950170-25-105825.md) | [51.8](/filings/0001193125-25-272321.md) | [53.4](/filings/0001850902-26-000008.md) | [53.4](/filings/0001193125-26-338178.md) | [53.5](/filings/0001193125-25-272321.md) | [53.6](/filings/0001850902-26-000008.md) | [53.6](/filings/0001193125-26-338178.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,688,246 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338178.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.